Quarterly Holdings Report
for
Fidelity® Select Portfolios®
Pharmaceuticals Portfolio
May 31, 2024
PHR-NPRT1-0724
1.802187.120
| Common Stocks - 99.5% | |||
| Shares | Value ($) | ||
| Biotechnology - 22.4% | |||
| Biotechnology - 22.4% | |||
| Acelyrin, Inc. | 180,373 | 743,137 | |
| Alnylam Pharmaceuticals, Inc. (a) | 14,671 | 2,177,617 | |
| Annexon, Inc. (a) | 291,889 | 1,409,824 | |
| Arcellx, Inc. (a) | 41,100 | 2,137,200 | |
| Arcus Biosciences, Inc. (a) | 318,000 | 4,792,260 | |
| ArriVent Biopharma, Inc. | 151,600 | 2,942,556 | |
| Ascendis Pharma A/S sponsored ADR (a) | 36,100 | 4,877,110 | |
| Avidity Biosciences, Inc. (a) | 641,700 | 17,236,062 | |
| Beam Therapeutics, Inc. (a) | 177,800 | 4,235,196 | |
| Biogen, Inc. (a) | 77,100 | 17,342,874 | |
| bluebird bio, Inc. (a)(b) | 2,226,000 | 2,010,968 | |
| Blueprint Medicines Corp. (a) | 244,600 | 25,819,976 | |
| CRISPR Therapeutics AG (a)(b) | 53,000 | 2,848,220 | |
| Cytokinetics, Inc. (a) | 23,100 | 1,120,581 | |
| Dyne Therapeutics, Inc. (a) | 984,300 | 31,379,484 | |
| Galapagos NV sponsored ADR (a) | 36,900 | 1,026,558 | |
| Generation Bio Co. (a)(b) | 715,276 | 2,274,578 | |
| Gilead Sciences, Inc. | 607,800 | 39,063,306 | |
| Insmed, Inc. (a) | 200,000 | 11,010,000 | |
| Intellia Therapeutics, Inc. (a) | 133,200 | 2,847,816 | |
| Leap Therapeutics, Inc. warrants 1/31/26 (a) | 60,600 | 70 | |
| Legend Biotech Corp. ADR (a) | 877,500 | 35,108,775 | |
| Merus BV (a) | 108,000 | 5,749,920 | |
| Moderna, Inc. (a) | 350,100 | 49,906,755 | |
| Monte Rosa Therapeutics, Inc. (a) | 796,400 | 3,281,168 | |
| NewAmsterdam Pharma Co. NV (a)(b) | 243,700 | 4,569,375 | |
| Prothena Corp. PLC (a) | 75,800 | 1,577,398 | |
| PTC Therapeutics, Inc. (a) | 260,900 | 9,486,324 | |
| Sarepta Therapeutics, Inc. (a) | 244,500 | 31,750,770 | |
| Spyre Therapeutics, Inc. (a) | 148,742 | 5,198,533 | |
| Xenon Pharmaceuticals, Inc. (a) | 226,000 | 8,603,820 | |
| 332,528,231 | |||
| Consumer Staples Distribution & Retail - 0.0% | |||
| Drug Retail - 0.0% | |||
| MedAvail Holdings, Inc. (a) | 66 | 0 | |
| Health Care Equipment & Supplies - 1.5% | |||
| Health Care Equipment - 1.5% | |||
| Inspire Medical Systems, Inc. (a) | 39,600 | 6,288,084 | |
| Ion Beam Applications SA (b) | 350,600 | 5,498,495 | |
| Nyxoah SA (a)(b) | 298,200 | 2,783,538 | |
| Nyxoah SA (a) | 140,500 | 1,322,105 | |
| Pulmonx Corp. (a) | 864,000 | 6,264,000 | |
| 22,156,222 | |||
| Health Care Providers & Services - 0.4% | |||
| Health Care Services - 0.4% | |||
| agilon health, Inc. (a) | 875,942 | 5,518,435 | |
| Life Sciences Tools & Services - 1.4% | |||
| Life Sciences Tools & Services - 1.4% | |||
| Gerresheimer AG | 177,200 | 20,298,506 | |
| Pharmaceuticals - 73.8% | |||
| Pharmaceuticals - 73.8% | |||
| Agomab Therapeutics SA warrants 10/10/33 (a)(c)(d) | 10 | 0 | |
| Arvinas Holding Co. LLC (a) | 26,300 | 871,582 | |
| AstraZeneca PLC sponsored ADR | 1,712,100 | 133,578,042 | |
| Axsome Therapeutics, Inc. (a) | 58,400 | 4,288,312 | |
| Bristol-Myers Squibb Co. | 744,500 | 30,591,505 | |
| Catalent, Inc. (a) | 228,900 | 12,312,531 | |
| Edgewise Therapeutics, Inc. (a) | 436,300 | 7,473,819 | |
| Elanco Animal Health, Inc. (a) | 773,000 | 13,666,640 | |
| Eli Lilly & Co. | 429,661 | 352,468,107 | |
| Fulcrum Therapeutics, Inc. (a)(b) | 683,600 | 5,366,260 | |
| Galderma Group AG | 92,240 | 7,527,253 | |
| GSK PLC sponsored ADR | 1,595,860 | 71,446,652 | |
| Harmony Biosciences Holdings, Inc. (a)(b) | 130,677 | 3,841,904 | |
| Indivior PLC (a) | 320,600 | 5,936,451 | |
| Merck & Co., Inc. | 557,136 | 69,942,853 | |
| Merck KGaA | 146,300 | 26,590,050 | |
| Novo Nordisk A/S Series B sponsored ADR | 1,603,900 | 216,975,592 | |
| Royalty Pharma PLC | 1,192,000 | 32,672,720 | |
| Sandoz Group AG ADR (b) | 4,979 | 176,705 | |
| Structure Therapeutics, Inc. ADR (a) | 54,000 | 1,846,800 | |
| UCB SA | 474,700 | 66,586,533 | |
| Zoetis, Inc. Class A | 172,100 | 29,181,276 | |
| 1,093,341,587 | |||
| TOTAL COMMON STOCKS (Cost $1,006,403,666) | 1,473,842,981 | ||
| Convertible Preferred Stocks - 0.4% | |||
| Shares | Value ($) | ||
| Biotechnology - 0.1% | |||
| Biotechnology - 0.1% | |||
| Castle Creek Biosciences, Inc.: | |||
| Series C (a)(c)(d) | 200 | 46,456 | |
| Series D1 (a)(c)(d) | 6,308 | 1,326,888 | |
| Series D2 (a)(c)(d) | 85 | 15,910 | |
| 1,389,254 | |||
| Financial Services - 0.1% | |||
| Diversified Financial Services - 0.1% | |||
| Paragon Biosciences Emalex Capital, Inc.: | |||
| Series C (a)(c)(d) | 158,879 | 1,881,127 | |
| Series D1 (a)(c)(d) | 14,400 | 171,072 | |
| Series D2 (a)(c)(d) | 22,477 | 253,765 | |
| 2,305,964 | |||
| Pharmaceuticals - 0.1% | |||
| Pharmaceuticals - 0.1% | |||
| Agomab Therapeutics SA Series C (c)(d) | 7,729 | 1,928,609 | |
| Software - 0.1% | |||
| Systems Software - 0.1% | |||
| Evozyne, Inc.: | |||
| Series A (a)(c)(d) | 5,900 | 98,412 | |
| Series B (c)(d) | 56,643 | 959,532 | |
| 1,057,944 | |||
| TOTAL CONVERTIBLE PREFERRED STOCKS (Cost $6,200,752) | 6,681,771 | ||
| Convertible Bonds - 0.1% | |||
Principal Amount (e) | Value ($) | ||
| Software - 0.1% | |||
| Systems Software - 0.1% | |||
Evozyne, Inc. 6% 9/13/28 pay-in-kind (c)(d) (Cost $907,225) | 907,225 | 980,710 | |
| Money Market Funds - 0.8% | |||
| Shares | Value ($) | ||
| Fidelity Cash Central Fund 5.39% (f) | 2,616,442 | 2,616,965 | |
| Fidelity Securities Lending Cash Central Fund 5.39% (f)(g) | 9,789,968 | 9,790,947 | |
| TOTAL MONEY MARKET FUNDS (Cost $12,407,912) | 12,407,912 | ||
| TOTAL INVESTMENT IN SECURITIES - 100.8% (Cost $1,025,919,555) | 1,493,913,374 |
NET OTHER ASSETS (LIABILITIES) - (0.8)% | (12,561,475) |
| NET ASSETS - 100.0% | 1,481,351,899 |
Legend
| (a) | Non-income producing |
| (b) | Security or a portion of the security is on loan at period end. |
| (c) | Restricted securities (including private placements) - Investment in securities not registered under the Securities Act of 1933 (excluding 144A issues). At the end of the period, the value of restricted securities (excluding 144A issues) amounted to $7,662,481 or 0.5% of net assets. |
| (d) | Level 3 security |
| (e) | Amount is stated in United States dollars unless otherwise noted. |
| (f) | Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request. |
| (g) | Investment made with cash collateral received from securities on loan. |
| Additional information on each restricted holding is as follows: | ||
| Security | Acquisition Date | Acquisition Cost ($) |
| Agomab Therapeutics SA warrants 10/10/33 | 10/03/23 | 0 |
| Agomab Therapeutics SA Series C | 10/03/23 | 1,687,596 |
| Castle Creek Biosciences, Inc. Series C | 12/09/19 | 82,370 |
| Castle Creek Biosciences, Inc. Series D1 | 4/19/22 | 1,356,409 |
| Castle Creek Biosciences, Inc. Series D2 | 6/28/21 | 14,700 |
| Evozyne, Inc. Series A | 4/09/21 | 132,573 |
| Evozyne, Inc. Series B | 9/14/23 | 877,400 |
| Evozyne, Inc. 6% 9/13/28 pay-in-kind | 9/14/23 - 3/13/24 | 907,225 |
| Paragon Biosciences Emalex Capital, Inc. Series C | 2/26/21 | 1,700,005 |
| Paragon Biosciences Emalex Capital, Inc. Series D1 | 10/21/22 | 155,952 |
| Paragon Biosciences Emalex Capital, Inc. Series D2 | 5/18/22 | 193,747 |
Affiliated Central Funds
Fiscal year to date information regarding the Fund's investments in Fidelity Central Funds, including the ownership percentage, is presented below.
| Affiliate | Value, beginning of period ($) | Purchases ($) | Sales Proceeds ($) | Dividend Income ($) | Realized Gain (loss) ($) | Change in Unrealized appreciation (depreciation) ($) | Value, end of period ($) | % ownership, end of period |
| Fidelity Cash Central Fund 5.39% | 14,130,101 | 180,001,889 | 191,515,410 | 282,426 | 385 | - | 2,616,965 | 0.0% |
| Fidelity Securities Lending Cash Central Fund 5.39% | 43,199,783 | 51,045,374 | 84,454,210 | 187,261 | - | - | 9,790,947 | 0.0% |
| Total | 57,329,884 | 231,047,263 | 275,969,620 | 469,687 | 385 | - | 12,407,912 | |
Amounts in the dividend income column in the above table include any capital gain distributions from underlying funds.
Amounts in the dividend income column for Fidelity Securities Lending Cash Central Fund represents the income earned on investing cash collateral, less rebates paid to borrowers and any lending agent fees associated with the loan, plus any premium payments received for lending certain types of securities.
Investment Valuation
Investments are valued as of 4:00 p.m. Eastern time on the last calendar day of the period. Securities transactions are accounted for as of trade date. The Board of Trustees (the Board) has designated the Fund's investment adviser as the valuation designee responsible for the fair valuation function and performing fair value determinations as needed. The investment adviser has established a Fair Value Committee (the Committee) to carry out the day-to-day fair valuation responsibilities and has adopted policies and procedures to govern the fair valuation process and the activities of the Committee. In accordance with these fair valuation policies and procedures, which have been approved by the Board, the Fund attempts to obtain prices from one or more third party pricing services or brokers to value its investments. When current market prices, quotations or currency exchange rates are not readily available or reliable, investments will be fair valued in good faith by the Committee, in accordance with the policies and procedures. Factors used in determining fair value vary by investment type and may include market or investment specific events, transaction data, estimated cash flows, and market observations of comparable investments. The frequency that the fair valuation procedures are used cannot be predicted and they may be utilized to a significant extent. The Committee manages the Fund's fair valuation practices and maintains the fair valuation policies and procedures. The Fund's investment adviser reports to the Board information regarding the fair valuation process and related material matters.
The inputs to valuation techniques used to value investments are categorized into a disclosure hierarchy consisting of three levels as shown below:
Level 1 - Unadjusted quoted prices in active markets for identical investments
Level 2 - other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, etc.)
Level 3 - unobservable inputs (including the Fund's own assumptions based on the best information available)
Valuation techniques used to value investments by major category are as follows:
Equity securities, including restricted securities, for which market quotations are readily available, are valued at the last reported sale price or official closing price as reported by a third party pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. In the event there were no sales during the day or closing prices are not available, securities are valued at the last quoted bid price or may be valued using the last available price and are generally categorized as Level 2 in the hierarchy. For any foreign equity securities, when market or security specific events arise, comparisons to the valuation of American Depositary Receipts (ADRs), futures contracts, Exchange-Traded Funds (ETFs) and certain indexes as well as quoted prices for similar securities may be used and would be categorized as Level 2 in the hierarchy. For equity securities, including restricted securities, where observable inputs are limited, assumptions about market activity and risk are used and these securities may be categorized as Level 3 in the hierarchy.
Debt securities, including restricted securities, are valued based on evaluated prices received from third party pricing services or from brokers who make markets in such securities. Convertible Bonds are valued by pricing services who utilize matrix pricing which considers yield or price of bonds of comparable quality, coupon, maturity and type or by broker-supplied prices. When independent prices are unavailable or unreliable, debt securities may be valued utilizing pricing methodologies which consider similar factors that would be used by third party pricing services. Debt securities are generally categorized as Level 2 in the hierarchy but may be Level 3 depending on the circumstances.
Investments in any open-end mutual funds are valued at their closing net asset value (NAV) each business day and are categorized as Level 1 in the hierarchy.
Changes in valuation techniques may result in transfers in or out of an assigned level within the disclosure hierarchy.
For additional information on the Fund's significant accounting policies, please refer to the Fund's most recent semiannual or annual shareholder report.
The fund's schedule of investments as of the date on the cover of this report has not been audited. This report is provided for the general information of the fund's shareholders. For more information regarding the fund and its holdings, please see the fund's most recent prospectus and annual report.
Third party trademarks and service marks are the property of their respective owners. All other trademarks and service marks are the property of FMR LLC or an affiliate.